Genmab As (OTCMKTS:GNMSF) was upgraded by Zacks Investment Research from a “strong sell” rating to a “hold” rating in a research report issued to clients and investors on Wednesday.
According to Zacks, “Genmab A/S is a biotechnology company that creates and develops human antibodies for the treatment of life-threatening and debilitating diseases. Genmab has numerous products in development to treat cancer, infectious disease, rheumatoid arthritis and other inflammatory conditions, and intends to continue assembling a broad portfolio of new therapeutic products. In addition, Genmab has developed UniBody, a new proprietary technology that creates a stable, smaller antibody format. Genmab has operations in Europe and the US. “
Separately, JPMorgan Chase & Co. downgraded shares of Genmab As from an “overweight” rating to a “neutral” rating in a research report on Friday, October 6th.
TRADEMARK VIOLATION NOTICE: “Genmab As (GNMSF) Stock Rating Upgraded by Zacks Investment Research” was reported by Ticker Report and is owned by of Ticker Report. If you are reading this piece on another domain, it was illegally stolen and reposted in violation of United States and international copyright legislation. The original version of this piece can be accessed at https://www.tickerreport.com/banking-finance/3126289/genmab-as-gnmsf-stock-rating-upgraded-by-zacks-investment-research.html.
Genmab As Company Profile
Genmab A/S, a biotechnology company, develops antibody therapeutics for the treatment of cancer in Denmark and internationally. The company markets Arzerra, a human monoclonal antibody for the treatment of chronic lymphocytic leukemia (CCL); and DARZALEX, a human IgG1k monoclonal antibody for the treatment of patients with multiple myeloma (MM).
Receive News & Ratings for Genmab As Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genmab As and related companies with MarketBeat.com's FREE daily email newsletter.